Welcome to our dedicated page for Onconetix news (Ticker: ONCO), a resource for investors and traders seeking the latest updates and insights on Onconetix stock.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on men’s health and oncology, and its news flow reflects that dual emphasis. Company press releases and SEC reports describe a portfolio that includes Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under IVDR, and ENTADFI, an FDA-approved, once-daily pill for the treatment of benign prostatic hyperplasia (BPH). News items often highlight clinical data, regulatory context, and commercialization steps for these assets.
Investors following ONCO news can expect updates on oncology diagnostics, particularly prostate cancer detection, and on men’s health therapeutics. For example, the company has reported new clinical validation data for Proclarix presented at the European Association of Urology congress, detailing performance in large patient cohorts and its potential to reduce unnecessary biopsies. Such news provides insight into how Onconetix positions Proclarix within established diagnostic pathways that rely on PSA testing and risk calculators.
Onconetix news also covers strategic transactions and partnerships. The company has announced the acquisition of Proteomedix, licensing agreements between Proteomedix and Immunovia related to the PancreaSure pancreatic cancer test, and, more recently, a non‑binding letter of intent and a definitive merger agreement with Ocuvex Therapeutics, Inc., followed by a joint announcement of the merger’s mutual termination. These items illustrate how the company evaluates business combinations and licensing to expand or refine its focus.
Another recurring theme in ONCO news is capital markets and listing compliance. Press releases discuss PIPE financings involving Series D and Series E preferred stock and warrants, an equity line of credit with Keystone Capital Partners, and a 1‑for‑85 reverse stock split implemented to address Nasdaq minimum bid price requirements. Updates on Nasdaq notices, hearings, and subsequent positive decisions by a Nasdaq Hearings Panel provide context for the company’s efforts to maintain its listing on The Nasdaq Capital Market.
By monitoring the ONCO news feed on this page, readers can track developments in Proclarix clinical evidence, ENTADFI commercialization, licensing arrangements in oncology diagnostics, and the company’s financing and corporate actions as disclosed in press releases and related SEC filings.
Onconetix (Nasdaq: ONCO) disclosed that Realbotix expects to deliver 19 previously ordered humanoid robots and related AI implementations across March, April, and May 2026 as it scales production capacity. Onconetix previously entered a definitive all-stock share exchange to acquire Realbotix LLC, with closing anticipated in 2H 2026, subject to shareholder and regulatory approvals. This update is provided for informational purposes and includes forward-looking statements; investors are cautioned against undue reliance.
Onconetix (Nasdaq: ONCO) announced leadership changes tied to a pending acquisition of Realbotix LLC on March 31, 2026. David White became CEO effective March 18, 2026; Sammy Dorf joined the Board and Audit Committee effective March 19, 2026. Karina Fedasz will remain Interim CFO.
The appointments are presented as strengthening governance and execution as the company advances a previously announced definitive agreement to acquire AI-powered humanoid robot developer Realbotix.
Onconetix (Nasdaq: ONCO) highlighted that Realbotix’s humanoid robot was featured as a live connected endpoint in Ericsson’s pre-standard 6G over-the-air trial at Ericsson’s U.S. headquarters in Plano, Texas on March 25, 2026. The robot streamed video and interacted in real time over Ericsson’s test network, demonstrating AI-agnostic integration across cloud and network environments. Onconetix reiterated its definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-stock transaction announced February 12, 2026; closing and Nasdaq listing are expected in the second half of 2026, subject to shareholder and regulatory approvals.
Onconetix (NASDAQ: ONCO) announced a 1-for-5 reverse stock split effective 12:01 a.m. ET on March 25, 2026.
The Board set the ratio after stockholder approval on February 3, 2026; shares outstanding will fall from ~3.6 million to ~0.7 million to help meet Nasdaq's $1.00 minimum bid requirement.
Onconetix (Nasdaq: ONCO) will acquire Realbotix LLC in an all-stock share exchange that transfers 100% of Realbotix equity to Onconetix. The combined company expects to trade on Nasdaq and the deal is targeted to close in the second half of 2026.
Following closing, Realbotix Parent is expected to own between 75% and 90% of fully diluted common shares; Andrew Kiguel will become CEO of the combined company. Closing remains subject to shareholder and regulatory approvals in the US and Canada.
Realbotix (ONCO) agreed on February 11, 2026 to sell 100% of its subsidiary Realbotix, LLC to NASDAQ-listed Onconetix (NASDAQ: ONCO) in an all-stock deal.
Realbotix will receive a variable 75%–90% stake of ONCO post-close, retain control of Abyss Creations, and can appoint four of five ONCO directors. Closing is expected before end of Q3 2026.
Onconetix (NASDAQ:ONCO), a biotechnology company focused on men's health and oncology, has announced multiple significant financial transactions. The company has secured a $12.9 million private placement through Series D Preferred Stock and Warrants, with $9.3 million paid in cash and the remainder offsetting existing debts.
The financing includes warrants to purchase up to 4,362,827 shares of common stock at an initial exercise price of $3.6896 per share. Additionally, Onconetix has settled its $8.8 million debt with Veru, Inc. through a combination of $6.3 million cash payment and conversion of $2.5 million into Series D Preferred Stock and warrants. The company has also terminated its previously planned merger with Ocuvex, Inc.
Onconetix (NASDAQ:ONCO) and Ocuvex Therapeutics have mutually agreed to terminate their merger agreement originally announced on July 16, 2025. The decision comes after both companies determined that pursuing independent paths would better serve their respective stakeholders.
Despite the merger termination, Ocuvex announced positive developments, including obtaining its New Jersey state pharmaceutical license and the upcoming commercial launch of Omlonti in the coming weeks. Both companies' leadership expressed confidence in their independent growth trajectories and maintained a collaborative spirit throughout the process.
Onconetix (NASDAQ:ONCO) announced that its subsidiary Proteomedix has entered into a licensing agreement with Immunovia AB for the manufacturing of key reagents used in their pancreatic cancer test PancreaSure. Under the agreement, Proteomedix will provide master cells for antibody production and intellectual property licenses for three of the five biomarkers in PancreaSure.
The deal includes payments totaling $700,000 to Proteomedix in 2025-2026, plus a 3% royalty on net sales of PancreaSure and related products from 2026 to 2032. The agreement enables Immunovia to purchase reagents directly from Proteomedix's supplier while maintaining their focus on Proclarix, their early prostate cancer detection test.
Onconetix (NASDAQ:ONCO) and privately-held Ocuvex Therapeutics have signed a definitive merger agreement in a significant stock-based transaction. Under the terms, Ocuvex shareholders will receive 90% ownership of the combined company, while Onconetix shareholders will retain 10% of the equity interests.
The merger will combine Ocuvex's pipeline of commercial and late clinical stage ophthalmic assets with Onconetix's public market presence. The combined company's board will consist of seven directors, with Ocuvex designating five and Onconetix appointing two. The transaction is expected to close in Q4 2025, subject to regulatory and stockholder approvals.